Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma

Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma CASE REPORT Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma Amber Kiyani, DDS,* Nyla A. Heerema, PhD,w Joel L. Mayerson, MD,z Thomas J. Scharschmidt, MD,z and Obiajulu H. Iwenofu, MDw myxoid end of the spectrum (myxoid liposarcoma) and Abstract: Myxoid liposarcomas are malignant lipomatous tu- the high-grade round cell type (round cell liposarcoma) mors with a predilection for young adults. They are charac- with both harboring the same defining t(12;16)(q13;p11.2) terized by the presence of reciprocal translocation between the 2 or t(12;22)(q13;q12) cytogenetic abnormality. Myxoid/ CHOP (DDIT3) gene on chromosome 12 and the FUS gene on round cell liposarcomas have a tendency to recur locally chromosome 16, t(12;16)(q13;p11.2) in >95% of cases, or less 1,3 and have a metastatic rate of about 30%. The prog- commonly, a translocation between the DDIT3 and EWSR1 nosis is dependent on the clinical stage and histologic genes, t(12;22)(q13;q12). Secondary aberrations involving tris- grade, as defined by the percentage of round cell omy 8 and chromosomes 1 and 16 have been reported. Herein, component within the tumor. Approximately, 95% of we report for the first time a novel secondary clonal trans- myxoid/round cell liposarcomas consistently show a location, t(2;4) (q23;p14) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma

Loading next page...
 
/lp/wolters-kluwer-health/novel-clonal-t-2-4-q23-p14-secondary-cytogenetic-abnormality-in-a-5UsggobsVl

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31829804f7
pmid
23958553
Publisher site
See Article on Publisher Site

Abstract

CASE REPORT Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma Amber Kiyani, DDS,* Nyla A. Heerema, PhD,w Joel L. Mayerson, MD,z Thomas J. Scharschmidt, MD,z and Obiajulu H. Iwenofu, MDw myxoid end of the spectrum (myxoid liposarcoma) and Abstract: Myxoid liposarcomas are malignant lipomatous tu- the high-grade round cell type (round cell liposarcoma) mors with a predilection for young adults. They are charac- with both harboring the same defining t(12;16)(q13;p11.2) terized by the presence of reciprocal translocation between the 2 or t(12;22)(q13;q12) cytogenetic abnormality. Myxoid/ CHOP (DDIT3) gene on chromosome 12 and the FUS gene on round cell liposarcomas have a tendency to recur locally chromosome 16, t(12;16)(q13;p11.2) in >95% of cases, or less 1,3 and have a metastatic rate of about 30%. The prog- commonly, a translocation between the DDIT3 and EWSR1 nosis is dependent on the clinical stage and histologic genes, t(12;22)(q13;q12). Secondary aberrations involving tris- grade, as defined by the percentage of round cell omy 8 and chromosomes 1 and 16 have been reported. Herein, component within the tumor. Approximately, 95% of we report for the first time a novel secondary clonal trans- myxoid/round cell liposarcomas consistently show a location, t(2;4) (q23;p14)

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Aug 1, 2015

There are no references for this article.